American Portfolios Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

American Portfolios Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-4,077	Closed	-$344K	–	2859
2019 Q2	$344K	Buy	4,077 +224	+6%	+$20.1K	0.03%	526
2019 Q1	$368K	Buy	3,853 +1,122	+41%	+$101K	0.03%	449
2018 Q4	$193K	Buy	+2,731	New	+$209K	0.02%	521
2018 Q3	–	Sell	-1,637	Closed	-$190K	–	2434
2018 Q2	$190K	Buy	1,637 +784	+92%	+$78.2K	0.03%	568
2018 Q1	$69K	Buy	853 +92	+12%	+$7.08K	0.01%	895
2017 Q4	$44.7K	Buy	+761	New	+$38.1K	0.01%	1041

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

American Portfolios Advisors's ENTA Position: Q3 2019 in Review

American Portfolios Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q3 2019, closing a stake of 4,077 shares — an estimated $344K sold.

American Portfolios Advisors first reported a position in ENTA in Q4 2017 and held it in 6 quarters. The position peaked at $368K in Q1 2019. 176 funds tracked by Wall St. Rank hold ENTA as of Q3 2019.

American Portfolios Advisors reported no remaining Enanta Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
American Portfolios Advisors sold 4,077 Enanta Pharmaceuticals shares in Q3 2019, an estimated $344K.
American Portfolios Advisors first reported a position in Enanta Pharmaceuticals in Q4 2017 and held it in 6 quarters.
American Portfolios Advisors's Enanta Pharmaceuticals position peaked at $368K in Q1 2019.
176 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2019.

Based on American Portfolios Advisors's 13F filing for Q3 2019, filed 24 Mar 2023.